stoxline Quote Chart Rank Option Currency Glossary
  
Precigen, Inc. (PGEN)
1.65  0.045 (2.8%)    07-23 16:00
Open: 1.61
High: 1.66
Volume: 505,983
  
Pre. Close: 1.605
Low: 1.6
Market Cap: 416(M)
Technical analysis
2024-07-23 4:54:28 PM
Short term     
Mid term     
Targets 6-month :  2.01 1-year :  2.25
Resists First :  1.72 Second :  1.92
Pivot price 1.6
Supports First :  1.39 Second :  1.16
MAs MA(5) :  1.64 MA(20) :  1.59
MA(100) :  1.48 MA(250) :  1.39
MACD MACD :  0 Signal :  0
%K %D K(14,3) :  40.5 D(3) :  43.6
RSI RSI(14): 53.1
52-week High :  1.92 Low :  0.83
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.
[ PGEN ] has closed below upper band by 39.0%. Bollinger Bands are 47.9% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 5 days. This is a sign that the current trend might continue.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 1.66 - 1.67 1.67 - 1.68
Low: 1.58 - 1.59 1.59 - 1.6
Close: 1.63 - 1.65 1.65 - 1.66
Company Description

Precigen, Inc. discovers and develops the next generation of gene and cellular therapies in the United States. It also provides disease-modifying therapeutics; genetically engineered swine for regenerative medicine applications; and reproductive and embryo transfer technologies. In addition, the company offers UltraVector platform that incorporates advanced DNA construction technologies and computational models to design and assemble genetic components into complex gene expression programs; mbIL15, a gene that enhances functional characteristics of immune cells; Sleeping Beauty, a non-viral transposon/transposase system; AttSite recombinases, which breaks and rejoins DNA at specific sequences; AdenoVerse technology platform, a library of engineered adenovector serotypes; and L. lactis is a food-grade bacterium. Additionally, it provides RheoSwitch, an inducible gene switch system that provides quantitative dose-proportionate regulation of the amount and timing of target protein expression; kill switches to selectively eliminate cell therapies in vivo; tissue-specific promoters; UltraCAR-T platform for the treatment of cancer; AdenoVerse Immunotherapy, a library of proprietary adenovectors for the gene delivery; and ActoBiotics platform, genetically modified bacteria that deliver proteins and peptides at mucosal sites. Precigen, Inc. has collaboration and license agreements with Alaunos Therapeutics, Inc.; Ares Trading S.A.; Oragenics, Inc.; Castle Creek Biosciences, Inc.; Intrexon Energy Partners, LLC; and Intrexon Energy Partners II, LLC. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in January 2020. Precigen, Inc. was founded in 1998 and is based in Germantown, Maryland.

Headline News

Tue, 23 Jul 2024
Precigen Appoints Phil Tennant as Chief Commercial Officer to Spearhead First Potential Gene Therapy Launch - Quantisnow

Tue, 23 Jul 2024
Precigen Appoints Phil Tennant as Chief Commercial Officer to Spearhead First Potential Gene Therapy Launch - StockTitan

Tue, 04 Jun 2024
Precigen (NASDAQ:PGEN) shareholders are up 15% this past week, but still in the red over the last three years - Simply Wall St

Mon, 03 Jun 2024
Precigen Announces Groundbreaking Pivotal Study Data for PRGN-2012 in Patients with Recurrent Respiratory Papillomatosis in Which More than Half of Patients Achieved Complete Response - PR Newswire

Tue, 14 May 2024
Precigen Reports First Quarter 2024 Financial Results and Business Updates - PR Newswire

Sat, 11 May 2024
Precigen, Inc.'s (NASDAQ:PGEN) Path To Profitability - Simply Wall St

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Outperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Outperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Underperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Neutral
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 0 (M)
Shares Float 252 (M)
Held by Insiders 1.3063e+008 (%)
Held by Institutions 11.4 (%)
Shares Short 13,320 (K)
Shares Short P.Month 0 (K)
Stock Financials
EPS -8.33e+007
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin 0 %
Operating Margin -2 %
Return on Assets (ttm) 292 %
Return on Equity (ttm) -29.9 %
Qtrly Rev. Growth 5.44e+006 %
Gross Profit (p.s.) -24.57
Sales Per Share -39.85
EBITDA (p.s.) 0
Qtrly Earnings Growth -0.4 %
Operating Cash Flow 0 (M)
Levered Free Cash Flow -63 (M)
Stock Valuations
PE Ratio -0.01
PEG Ratio -1.9
Price to Book value 0
Price to Sales -0.05
Price to Cash Flow 7.31
Stock Dividends
Dividend 0
Forward Dividend 1.316e+007
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android